{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T18:42:33Z","timestamp":1747075353679},"reference-count":38,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T00:00:00Z","timestamp":1120176000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2005,7]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To identify clinical factors associated with HIV\u2010associated lipoatrophy and to evaluate body composition changes, blood pressure and lipid levels in lipoatrophic subjects 3\u20134 years after the atrophy diagnosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Clinical signs of lipoatrophy were assessed in 308 ambulant HIV\u2010positive patients in 2000\u20132001. Possible clinical risk factors, such as age, gender, race, wasting, duration of HIV infection, presence or absence of AIDS diagnosis, viral load and CD4 count, and detailed information about drug treatment were analysed and explored in a multivariate model. Lipoatrophic white males with triceps skin fold &lt;10\u2003mm were re\u2010examined after 44 months. Signs of lipoatrophy and associated factors, blood pressure, lipid levels, diet and level of exercise at first and second visits were compared.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In the multivariate analysis, significant clinical risk factors for lipoatrophy were weight loss &gt;7\u2003kg compared to normal weight [odds ratio (OR) 3.76; 95% confidence interval (CI) 1.80\u20137.82; <jats:italic>P<\/jats:italic>&lt;0.001], current and\/or previous use of stavudine (OR 3.72; 95% CI 1.57\u20138.83; <jats:italic>P<\/jats:italic>=0.003) and duration of HIV infection &gt;80 months (OR 2.28; 95% CI 1.13\u20134.59; <jats:italic>P<\/jats:italic>=0.021). Forty of 47 lipoatrophic white males with skin fold&lt;10\u2003mm were available for re\u2010examination. Of these, 15 (38%) no longer fulfilled the atrophy diagnosis (<jats:italic>P&lt;<\/jats:italic>0.001). The prevalence of arm atrophy fell from 63 to 28% (<jats:italic>P=<\/jats:italic>0.001) and facial atrophy from 55 to 43% (<jats:italic>P=<\/jats:italic>0.23). Use of stavudine for&lt;36 months was significantly associated with lipoatrophy reversal (OR 5.00; 95% CI 1.15\u201321.80; <jats:italic>P<\/jats:italic>=0.032), but weight gain and increased CD4 count were not. Prevalence of hypertension increased from 28 to 50% (<jats:italic>P=<\/jats:italic>0.035), mean systolic blood pressure from 130\u00b114 to 136\u00b119\u2003mmHg (<jats:italic>P=<\/jats:italic>0.021) and diastolic blood pressure from 82\u00b110 to 87\u00b112\u2003mmHg (<jats:italic>P&lt;<\/jats:italic>0.001). In spite of increased use of lipid\u2010lowering drugs (from two to nine patients), levels of total cholesterol, high\u2010density lipoprotein (HDL) cholesterol and triglycerides were unchanged.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this study, we found that weight loss &gt;7\u2003kg, use of stavudine and long duration of HIV infection were significant risk factors for clinical lipoatrophy. Clinical lipoatrophy was partly reversible, and &lt;36 months on stavudine was significantly associated with atrophy reversal. The prevalence of hypertension and the yearly increase of mean blood pressure were disturbingly high in these patients. However, the number of patients in this study was limited, and prospective studies in larger cohorts are required to confirm these findings.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2005.00305.x","type":"journal-article","created":{"date-parts":[[2005,7,1]],"date-time":"2005-07-01T17:21:05Z","timestamp":1120238465000},"page":"260-267","source":"Crossref","is-referenced-by-count":11,"title":["Lipoatrophic men 44 months after the diagnosis of lipoatrophy are less lipoatrophic but more hypertensive"],"prefix":"10.1111","volume":"6","author":[{"given":"BM","family":"Bergersen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L","family":"Sandvik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I","family":"Ellingsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JN","family":"Bruun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2005,7]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_5_3_2","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1097\/00002030-199905070-00009","article-title":"Reversion of metabolic abnormalities after switching from HIV\u20101 protease inhibitors to nevirapine","volume":"13","author":"Martinez E","year":"1999","journal-title":"AIDS"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021589"},{"key":"e_1_2_5_5_2","first-page":"1811","article-title":"HIV protease inhibitor substitution in patients with lipodystrophy","volume":"15","author":"Carr A","year":"2001","journal-title":"a randomized, controlled, open-label, multicentre study"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200007070-00002"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-200107010-00004"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200305020-00005"},{"key":"e_1_2_5_9_2","first-page":"2447","article-title":"Increased risk of lipoatrophy under stavudine in HIV\u20101\u2010infected patients","volume":"16","author":"Joly V","year":"2002","journal-title":"results of a substudy from a comparative trial"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200301010-00007"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200305010-00004"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200305010-00005"},{"key":"e_1_2_5_13_2","first-page":"263","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus\u2010infected patients switched from stavudine to abacavir or zidovudine","volume":"38","author":"McComsey GA","year":"2004","journal-title":"the results of the TARHEEL study"},{"key":"e_1_2_5_14_2","first-page":"731","article-title":"Prevalence of hypertension in HIV\u2010positive patients on highly active retroviral therapy (HAART) compared with HAART\u2010naive and HIV\u2010negative controls","volume":"22","author":"Bergersen BM","year":"2003","journal-title":"results from a Norwegian study of 721 patients"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1080\/00365540410019273"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1258\/0956462053888808"},{"key":"e_1_2_5_17_2","first-page":"625","article-title":"Elevated Framingham risk score in HIV\u2010positive patients on highly active antiretroviral therapy","volume":"23","author":"Bergersen BM","year":"2004","journal-title":"results from a Norwegian study of 721 subjects"},{"key":"e_1_2_5_18_2","volume-title":"Anthropometric Standardization Reference Manual","author":"Lohman TG","year":"1988"},{"key":"e_1_2_5_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000107251.49515.c2"},{"key":"e_1_2_5_20_2","unstructured":"Norwegian Institute of Public HealthMain Questionnaire Oslo Health Study 2000\u201301 (HUBRO).http:\/\/www.fhi.no\/dav\/66091FDE33734FAB96849B26D9F46333.pdf"},{"key":"e_1_2_5_21_2","first-page":"726","article-title":"An objective case definition of lipodystrophy in HIV\u2010infected adults","volume":"361","author":"Carr A","year":"2003","journal-title":"a case\u2013control study"},{"key":"e_1_2_5_22_2","volume-title":"Revised Classification System for HIV Infection and Expanded Surveillance Case Definition for AIDS Among Adolescents and Adults","author":"Castro KG","year":"1993"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200409240-00003"},{"key":"e_1_2_5_24_2","first-page":"1029","article-title":"Reversibility of lipoatrophy in HIV\u2010infected patients 2 years after switching from a thymidine analogue to abacavir","volume":"18","author":"Martin A","year":"2004","journal-title":"the MITOX Extension Study"},{"key":"e_1_2_5_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(91)91294-5"},{"key":"e_1_2_5_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)06102-4"},{"key":"e_1_2_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08094-7"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200012010-00004"},{"key":"e_1_2_5_29_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200301030-00017"},{"issue":"5","key":"e_1_2_5_30_2","first-page":"31","article-title":"Epidemiological evidence of increasing blood pressure in HIV\u20101\u2010infected individuals in the era of HAART. 2nd International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, Toronto, Canada, 13\u201315th September 2000","volume":"5","author":"Chow D","year":"2000","journal-title":"Antiviral Ther"},{"key":"e_1_2_5_31_2","article-title":"Different systolic blood pressure in HIV infected patients with and without antiretroviral therapy","author":"Bergersen BM","journal-title":"2nd Workshop of Lipodystrophy"},{"key":"e_1_2_5_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200110190-00013"},{"key":"e_1_2_5_33_2","first-page":"1377","article-title":"Hypertension among HIV patients","volume":"21","author":"Gazzaruso C","year":"2003","journal-title":"prevalence and relationships to insulin resistance and metabolic syndrome"},{"key":"e_1_2_5_34_2","first-page":"715","article-title":"Long term effects of smoking on physical fitness and lung function","volume":"311","author":"Sandvik L","year":"1995","journal-title":"a longitudinal study of 1393 middle aged Norwegian men for seven years"},{"key":"e_1_2_5_35_2","doi-asserted-by":"publisher","DOI":"10.1310\/5E7Q-PGWB-16UE-J48U"},{"key":"e_1_2_5_36_2","unstructured":"SeabergEC MunozA LuMet al.HIV infection HAART and blood pressure: results from the Multicenter AIDS Cohort Study (MACS).10th Conference on Retroviruses and Opportunistic Infections. Boston MA February 2003 [Abstract P744]."},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.3109\/10623320009072210"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200404300-00012"},{"key":"e_1_2_5_39_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000124480.32233.8A"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2005.00305.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2005.00305.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T15:22:21Z","timestamp":1696951341000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2005.00305.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2005,7]]}},"alternative-id":["10.1111\/j.1468-1293.2005.00305.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2005.00305.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7]]}}}